Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain.

Autor:	Haanpää, M., Cruccu, G., Nurmikko, T.J., McBride, W.T., Docu Axelarad, A., Bosilkov, A., Chambers, C., Ernault, E., Abdulahad, A.K.
Předmět:	THERAPEUTIC use of capsaicin PAIN management CAPSAICIN COMPARATIVE studies DRUG administration RESEARCH methodology MEDICAL cooperation NEURALGIA ORAL drug administration RESEARCH TRANSDERMAL medication EVALUATION research PAIN measurement RANDOMIZED controlled trials TREATMENT effectiveness
Zdroj:	European Journal of Pain; Feb2016, Vol. 20 Issue 2, p316-328, 13p
Abstrakt:	Background: Clinical trials have not yet compared the efficacy of capsaicin 8% patch with current standard therapy in peripheral neuropathic pain (PNP).Objectives: Head-to-head efficacy and safety trial comparing the capsaicin patch with pregabalin in PNP.Methods: Open-label, randomized, multicentre, non-inferiority trial. Patients with PNP, aged 18-80 years, were randomly assigned to either the capsaicin 8% patch (n = 282) or an optimised dose of oral pregabalin (n = 277), and assessed for a ≥30% mean decrease in Numeric Pain Rating Scale (NPRS) score from baseline to Week 8. Secondary endpoints included optimal therapeutic effect (OTE), time-to-onset of pain relief and treatment satisfaction.Results: The capsaicin 8% patch was non-inferior to pregabalin in achievement of a ≥30% mean decrease in NPRS score from baseline to Week 8 (55.7% vs. 54.5%, respectively; Odds ratio: 1.03 [95% CI: 0.72, 1.50]). The proportion of patients achieving OTE at Week 8 was 52.1% for the capsaicin 8% patch versus 44.8% for pregabalin (difference: 7.3%; 95% CI: -0.9%, 15.6%). The median time-to-onset of pain relief was significantly shorter for capsaicin 8% patch versus pregabalin (7.5 vs. 36.0 days; Hazard ratio: 1.68 [95% CI: 1.35, 2.08]; p < 0.0001). Treatment satisfaction was also significantly greater with the capsaicin 8% patch versus pregabalin. TEAEs were mild-to-moderate in severity, and resulted in treatment discontinuation only with pregabalin (n = 24). Systemic adverse drug reactions ranged from 0 to 1.1% with capsaicin 8% patch and 2.5 to 18.4% with pregabalin.Conclusions: The capsaicin 8% patch provided non-inferior pain relief to an optimized dose of pregabalin in PNP, with a faster onset of action, fewer systemic side effects and greater treatment satisfaction. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text